WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden,
D-Ore., and senior committee member Chuck Grassley, R-Iowa, today
released comments from the health care and patient community in response
to the policy questions raised in their report,
“The Price of Sovaldi and Its Impact on the U.S. Health Care System,”
released on December 1, 2015. The report examined how Gilead Sciences,
Inc. developed, priced, marketed and sold the hepatitis C drug, Sovaldi,
and its follow-on drug, Harvoni. The submissions can be found here.
“We thank all those who sent constructive, substantial comments on how new drugs are changing the health care system, and the challenges that creates for Medicare, Medicaid, and private health programs alike,” Wyden and Grassley said. “This feedback will be thoughtfully reviewed as we consider how to address policy issues such as the financial impact of expensive breakthrough drugs, patient access, and marketplace transparency.”
Wyden and Grassley previously requested comment on January 21, 2016. The senators received 63 comments from individuals, organizations and businesses.
“We thank all those who sent constructive, substantial comments on how new drugs are changing the health care system, and the challenges that creates for Medicare, Medicaid, and private health programs alike,” Wyden and Grassley said. “This feedback will be thoughtfully reviewed as we consider how to address policy issues such as the financial impact of expensive breakthrough drugs, patient access, and marketplace transparency.”
Wyden and Grassley previously requested comment on January 21, 2016. The senators received 63 comments from individuals, organizations and businesses.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.